Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ACTRN12626000289314) titled 'A Phase 1b study evaluating the safety and preliminary efficacy of AXA-042 monotherapy in patients with advanced solid tumours' on March 5.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Safety
Primary Sponsor: Axelia Oncology Pty Ltd
Condition:
Advanced solid tumours
Advanced solid tumours
Cancer - Kidney
Cancer - Other cancer types
Intervention:
Participants will receive AXA-042 as monotherapy administered by intravenous infusion once every 3 weeks (21-day treatment cycle). The do...